Precise and imprecise therapeutic targeting of sarcomas across the age spectrum
The biological and clinical diversity of sarcomas represents both a scientific opportunity and a medical challenge. Although cytotoxic chemotherapy can be curative for an important subset of patients, advances in technology have allowed us to identify mechanisms of oncogenic drivers and therapeutically target different subtypes of mesenchymal malignancies to improve clinical outcomes. Extrapolating from sarcoma, many of the lessons about therapeutic targeting and mechanisms of sensitivity and resistance have implications for other common forms of cancer, as well as inflammatory and fibrotic diseases. An overview of these promising and inter-related fields of research and clinical care will be presented with an eye towards the future convergence of research and patient care.
Prof., Harvard Medical School, Boston USA
Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Boston USA